Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of camrelizumab plus apatinib in previously treated advanced or recurrent endometrial cancer
ChiCTR2000031932Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in endometrial cancer (EC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Aug 2019; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2000031932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031932.